rethinkPeptides Search
Menu
Study breakdown

Lactoferricin Kills Leukemia Cells by Triggering the Ceramide Death Pathway

In VitroPreliminary evidence
The takeaway

Bovine lactoferricin's anticancer activity against leukemia was enhanced by modulating ceramide metabolism, identifying the ceramide-mediated apoptotic pathway as the mechanism for peptide-induced cancer cell death.

Key finding

Lactoferricin B induced leukemia cell apoptosis through ceramide accumulation, and modulating ceramide metabolism (glucocerebrosidase inhibition) pote

What the researchers found

Lactoferricin B induced leukemia cell apoptosis through ceramide accumulation, and modulating ceramide metabolism (glucocerebrosidase inhibition) potentiated the killing — identifying the ceramide death pathway as the molecular mechanism for this anticancer peptide.

Why it matters

Relevant for antimicrobial-peptides, cancer.

How the study worked

in-vitro study.

What this study cannot tell us

See abstract.

How to read the evidence

preliminary evidence.

When this study was published

Published in 2008.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Lactoferricin Kills Leukemia Cells by Triggering the Ceramide Death Pathway
What was found?
Bovine lactoferricin's anticancer activity against leukemia was enhanced by modulating ceramide metabolism, identifying the ceramide-mediated apoptotic pathway as the mechanism for peptide-induced cancer cell death.

Read the original research

Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.

International journal of oncology, 32(3), 537-44

Citation

Furlong, Suzanne J; Ridgway, Neale D; Hoskin, David W. (2008). Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.. International journal of oncology, 32(3), 537-44.